Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Mesenchymal stem cell therapy-Longeveron (Primary) ; Influenza virus vaccine
Indications Asthenia
Focus Adverse reactions; Therapeutic Use
Acronyms HERA
Sponsors Longeveron

31 May 2022 Status changed from active, no longer recruiting to completed.
04 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Apr 2022.
12 Nov 2021 According to a Longeveron media release, topline results from the trial are anticipated in Q1 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com